阿托伐他汀联合曲美他嗪治疗冠心病的疗效分析  

Analysis of the Efficacy of Atorvastatin Combined with Trimetazidine in the Treatment of Coronary Artery Disease

作　　者：石健[1] 赵莉[2] 杜峰[3] SHI Jian;ZHAO Li;DU Feng(Out-patient Department,the First People's Hospital of Guiyang,Guiyang,Guizhou Province,550002 China;Medi-cal Department,the First People's Hospital of Guiyang,Guiyang,Guizhou Province,550002 China;Department of Cardiology,the First People's Hospital of Guiyang,Guiyang,Guizhou Province,550002 China)

机构地区：[1]贵阳市第一人民医院门诊部,贵州贵阳550002 [2]贵阳市第一人民医院医务科,贵州贵阳550002 [3]贵阳市第一人民医院心内科,贵州贵阳550002

出　　处：《系统医学》2022年第23期116-120,共5页Systems Medicine

基　　金：贵阳市高层次创新型青年卫生人才项目[(2017)筑卫科技合同字第008号]。

摘　　要：目的研究阿托伐他汀联合曲美他嗪治疗冠心病的疗效。方法选取2020年1月—2021年8月贵阳市第一人民医院收治的冠心病患者86例为研究对象,随机分为对照组(43例,采用曲美他嗪治疗)与观察组(43例,曲美他嗪联合阿托伐他汀治疗),观察两组患者血管内皮功能、心功能、炎性因子、心血管事件发生率。结果治疗后,观察组一氧化氮(NO)、血清内皮素-1(ET-1)、外周血循环内皮微颗粒(cEMPS)均优于对照组,差异有统计学意义(P<0.05);治疗后,观察组左室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、舒张末期左心室后壁厚度(LVPWd)均优于对照组,差异有统计学意义(P<0.05);治疗后,观察组血清基质金属蛋白酶-9(MMP-9)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)均优于对照组,差异有统计学意义(P<0.05);观察组心血管事件发生率(0.00%)低于对照组(16.28%),差异有统计学意义(χ^(2)=5.598,P<0.05)。结论给予冠心病患者阿托伐他汀联合曲美他嗪治疗,能改善患者血管内皮功能及心功能,减轻炎症反应,减少心血管事件的发生。Objective To study the efficacy of atorvastatin combined with trimetazidine in the treatment of coronary ar⁃tery disease.Methods 86 patients with coronary heart disease admitted to the First People's Hospital of Guiyang from January 2020 to August 2021 were selected as the study subjects and randomly divided into control group(43 cases,treated with trimetazidine)and observation group(43 cases,trimetazidine combined with atorvastatin).The vascular endothelial function,cardiac function,inflammatory factors,and cardiovascular event rates were observed between the two groups.Results After treatment,nitric oxide(NO),serum endothelin-1(ET-1),and peripheral blood circulation endothelial microparticles(cEMPS)in the observation group were better than those in the control group,and the differ⁃ence was statistically significant(P<0.05);after treatment,left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),and end-diastolic left ventricular posterior wall thickness(LVPWd)in the observa⁃tion group were better than those in the control group,and the difference was statistically significant(P<0.05);after treatment,serum matrix metalloproteinase-9(MMP-9),hypersensitive C-reactive protein(hs-CRP),and tumor necro⁃sis factor-α(TNF-α)in the observation group were better than those in the control group,and the difference was sta⁃tistically significant(P<0.05).The incidence of cardiovascular events in the observation group(0.00%)was lower than that in the control group(16.28%),and the difference was statistically significant(χ^(2)=5.598,P<0.05).Conclusion The treatment of atorvastatin combined with trimetazidine in patients with coronary heart disease can improve vascular endothelial function and cardiac function,reduce inflammatory reaction and reduce the occurrence of cardiovascular events.

关 键 词：阿托伐他汀 曲美他嗪 冠心病 疗效 

分 类 号：R4[医药卫生—临床医学]